openPR Logo
Press release

Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics-Pipeline Analysis 2018

04-02-2019 02:04 PM CET | Health & Medicine

Press release from: Pharma Proff

Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics-Pipeline

Spleen tyrosine kinase (Syk) is a protein that belongs to the family of tyrosine kinases with an ability to initiate the inflammatory responses, by connecting immune cell receptors to intracellular signaling pathways. Therefore, Syk is an attractive target for improving the symptoms related to acute and chronic inflammation. In addition, the role of protein is recognized as a promoter in various types of cancers ranging from leukemia to retinoblastoma.

Download the sample report @

Syk protein facilitates the phosphorylation of protein on tyrosines and also involves in the B cell antigen receptor (BCR) signalling pathways. There are several drugs that effectively inhibit the Syk kinase but the off-target effect is a limiting factor. Currently, there are various Syk inhibitors that prevent release of inflammatory cytokines in vitro and IgE-driven mast cell degranulation.

Get the detailed analysis @

Levolta Pharmaceuticals Inc. is developing a drug candidate, that acts as Syk inhibitor for the treatment of immunological diseases. Rigel Pharmaceuticals Inc. is developing fostamatinib as a Syk inhibitor for the treatment of chronic immune thrombocytopenia and autoimmune hemolytic anemia. Hutchison China MediTech Limited is also developing HMPL-523 as a Syk inhibitor for the treatment of cancer indications. Some of the companies having pipeline of Syk inhibitor include Genosco Inc., Asana BioSciences LLC, and others.

Make enquiry before purchase @

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics-Pipeline Analysis 2018 here

News-ID: 1683610 • Views: 223

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for Syk

Investigation announced for Long-Term Investors in shares of Stryker Corporation …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Stryker Corporation. Investors who purchased shares of Stryker Corporation (NYSE: SYK) have certain options and should contact the Shareholders Foundation at or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Stryker officers and directors breached their fiduciary duties and caused damage to the company and its shareholders. On April 6,
Investigation announced for Investors in shares of Stryker Corporation (NYSE: SY …
An investigation was announced concerning potential securities laws violations by Stryker Corporation in connection with certain financial statements. Investors who purchased shares of Stryker Corporation (NYSE: SYK), have certain options and should contact the Shareholders Foundation at or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Stryker Corporation regarding its business, its prospects and its operations were materially false and
Tyrosine Protein Kinase SYK Market Trends, Size, Competitive Analysis and Foreca …
The global tyrosine protein kinase SYK market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Tyrosine protein kinase SYK is also known as spleen tyrosine kinase (SYK). It is a non-receptor cytoplasmic enzyme and is primarily expressed in cells of hematopoietic lineage. It contains two adjacent SH2 domains that bind to immunoreceptor tyrosine-based activation motifs (ITAMs) to activate the enzyme. The major factor driving the
Orthopedic Surgical Robots Market 2019 Key Trend, Future Opportunities Forecast …
Orthopedic surgical robots refer to the man-made robots that are specially designed to assist surgeons during orthopedic surgeries. Ever since the launch of these specialized robots and constant innovations, the orthopedic surgeries, surgeons, as well as the patients have been benefitting in terms of better outcomes, improved assistance, and approval of patients for surgery, respectively. FDA approved first robot for surgery in 2000 after which several complex surgeries were performed
Global Tyrosine Protein Kinase SYK Market Research 2019
In this report, we analyze the Tyrosine Protein Kinase SYK Market from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value,
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7. …
Market Research Hub report titled ‘Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC pipeline' Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or